Fig. 3.

Radiation followed by CMP-001 led to inhibited tumor growth and improved survival rates in a colon carcinoma mouse model. (A) Mice (n = 5/group) were inoculated in the hind legs with CT26 cancer cells, with the right leg considered the “primary” tumor (and therefore irradiated with high-dose radiotherapy [RT]) and the left leg considered the abscopal tumor (and therefore irradiated with low-dose RT). Mice were treated with RT, CMP-001, or RT+ CMP-001 as shown. (B) Survival of mouse treatment groups indicated prolonged survival after RT (three 12-Gy fractions to the primary tumor and two 1-Gy fractions to the abscopal tumor) followed by adjuvant CMP-001) (p = 0.0797, n.s. vs RT only) and (p = 0.0023 vs CMP-001 only group). (C, D) Tumor growth curves indicated that RT (three 12-Gy fractions to the primary tumor and two 1-Gy fractions to the abscopal tumor) followed by adjuvant CMP-001 had superior antitumor activity relative to the other treatment conditions. The addition of α-PD1 and α-OX40 did not extend survival of high dose + low dose RT + CMP-001 treatment. However, high dose + low dose RT led to significant delay in tumor growth when added to triple immunotherapy (CMP-001 + α-OX40 + α-PD1) vs. triple immunotherapy alone (p = 0.0291). Data are expressed as mean diameters from each mouse at each time point, and reported as Mean ± SEM.